Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer
Open Access
- 22 April 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 32 (7), 1050-1056
- https://doi.org/10.1093/carcin/bgr067
Abstract
The magnitude of benefit is variable for advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy. The purpose of this study is to determine whether genetic variations in the transforming growth factor-beta (TGF-β) pathway are associated with clinical outcomes in NSCLC patients receiving first-line platinum-based chemotherapy. Five hundred and ninety-eight advanced-stage NSCLC patients who received first-line platinum-based chemotherapy with or without radiotherapy were recruited at the MD Anderson Cancer Center between 1995 and 2007. DNA from blood was genotyped for 227 single nucleotide polymorphisms (SNPs) in 23 TGF-β pathway-related genes to evaluate their associations with overall survival. In individual SNP analysis, 22 variants were significantly associated with overall survival, of which the strongest associations were found for BMP2:rs235756 [hazard ratio (HR) = 1.45; 95% confidence interval (CI), 1.11–1.90] and SMAD3:rs4776342 (HR = 1.25; 95% CI, 1.06–1.47). Fifteen and 18 genetic loci displayed treatment-specific associations for chemotherapy and chemoradiation, respectively, identifying a majority of the cases who would be predicted to respond favorably to a specific treatment regimen. BMP2:rs235753 and a haplotype in SMAD3 were associated with overall survival for both treatment modalities. Cumulative effect analysis showed that multiple risk genotypes had a significant dose-dependent effect on overall survival (Ptrend = 2.44 x 10−15). Survival tree analysis identified subgroups of patients with dramatically different median survival times of 45.39 versus 13.55 months and 18.02 versus 5.89 months for high- and low- risk populations when treated with chemoradiation and chemotherapy, respectively. These results suggest that genetic variations in the TGF-β pathway are potential predictors of overall survival in NSCLC patients treated with platinum-based chemotherapy with or without radiation.Keywords
This publication has 40 references indexed in Scilit:
- Haplotype Association Mapping of Acute Lung Injury in Mice Implicates Activin A Receptor, Type 1American Journal of Respiratory and Critical Care Medicine, 2011
- TGFBR1 Haplotypes and Risk of Non–Small-Cell Lung CancerCancer Research, 2009
- BMP-2 signaling in ovarian cancer and its association with poor prognosisJournal of Ovarian Research, 2009
- The TGF-β paradox in human cancer: an updateFuture Oncology, 2009
- Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With ChemoradiotherapyJournal of Clinical Oncology, 2009
- Non-Smad pathways in TGF-β signalingCell Research, 2008
- Common Variants in the BMP2, BMP4, and HJV Genes of the Hepcidin Regulation Pathway Modulate HFE Hemochromatosis PenetranceAmerican Journal of Human Genetics, 2007
- Bone Morphogenetic Protein 2 Activates Smad6 Gene Transcription through Bone-specific Transcription Factor Runx2Journal of Biological Chemistry, 2007
- Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signalingProceedings of the National Academy of Sciences of the United States of America, 2007
- Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapyLeukemia, 2003